Millenium takes "safer" & "less expensive" synthetic bone graft to the European market
This article was originally published in Clinica
Executive Summary
Millenium Biologix is gearing up to sell in Europe a bone graft substitute that it believes is so strongly differentiated from competing products that it will be "uniquely positioned to gain market share".